1. Home
  2. HOPE vs NVAX Comparison

HOPE vs NVAX Comparison

Compare HOPE & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hope Bancorp Inc.

HOPE

Hope Bancorp Inc.

HOLD

Current Price

$13.00

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.05

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOPE
NVAX
Founded
1986
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2000
1996

Fundamental Metrics

Financial Performance
Metric
HOPE
NVAX
Price
$13.00
$9.05
Analyst Decision
Buy
Hold
Analyst Count
2
9
Target Price
$14.50
$11.33
AVG Volume (30 Days)
707.3K
4.8M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
4.53%
N/A
EPS Growth
N/A
309.76
EPS
0.23
N/A
Revenue
N/A
$1,123,479,000.00
Revenue This Year
$42.00
N/A
Revenue Next Year
$19.66
N/A
P/E Ratio
$56.04
N/A
Revenue Growth
N/A
64.69
52 Week Low
$9.44
$6.20
52 Week High
$13.09
$11.85

Technical Indicators

Market Signals
Indicator
HOPE
NVAX
Relative Strength Index (RSI) 64.24 45.45
Support Level $12.17 $8.89
Resistance Level N/A $9.02
Average True Range (ATR) 0.24 0.68
MACD 0.05 -0.21
Stochastic Oscillator 91.10 18.10

Price Performance

Historical Comparison
HOPE
NVAX

About HOPE Hope Bancorp Inc.

Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: